Multi-Fractional Immunoisolating Device for Human Ovarian Tissue

TECHNOLOGY NUMBER: 2020-052
Technology No. 2020-052

OVERVIEW

A tunable immunoisolating hydrogel device for human ovarian tissue transplantation.

  • Accommodates massive volumetric expansion while preventing capsule failure and immune rejection.
  • Treatment of premature ovarian insufficiency, restoration of endocrine function, and pediatric cancer survivor care.

BACKGROUND

Premature ovarian insufficiency often affects pediatric cancer patients, leading to a loss of essential endocrine function that impairs natural puberty. To restore hormonal balance and biological function, tissue delivery systems have been explored. Previous approaches utilized dual-core poly(ethylene glycol) hydrogels to support murine tissue encapsulation. However, human ovarian tissue undergoes approximately forty times larger volumetric expansion during follicle growth compared to murine counterparts. This massive volume increase leads to mechanical stress and capsule failure in existing rigid bulk hydrogel matrices. Additionally, transplanted allogeneic tissue must be shielded from host immune cell infiltration without suppressing the exchange of essential nutrients, oxygen, follicle-stimulating hormone, and luteinizing hormone. Consequently, a critical need exists for advanced delivery systems that provide robust immunoisolation while dynamic tissue expansion occurs.


INNOVATION

The proposed technology features a multi-fractional immunoisolating hydrogel device designed specifically to accommodate human ovarian tissue growth. Instead of a static bulk hydrogel core, the system utilizes degradable poly(ethylene glycol) microparticles synthesized via electrospraying a precursor solution containing eight-arm poly(ethylene glycol)-vinyl sulfone and a YKNS peptide crosslinker. This microparticle-based structure creates a flexible internal environment that expands along with growing tissue, preventing structural capsule breakdown. The outer hydrogel shell acts as a selective barrier, blocking host immune cells while permitting essential nutrient diffusion and the release of estradiol and progesterone. Advanced fabrication methods, including three-dimensional printing for multiplexing, further enhance structural control. This bioengineering approach provides critical endocrine restoration and offers a durable therapeutic solution for pediatric cancer survivors suffering from premature ovarian insufficiency.


ADDITIONAL INFORMATION

INTELLECTUAL PROPERTY

Patent Pending


RELATED TECHNOLOGY


  • expand_more mode_edit Inventor (2)
    Ariella Shikanov
    Margaret Brunette
  • expand_more cloud_download Supporting documents (1)
    Product brochure
    Multi-Fractional Immunoisolating Device for Human Ovarian Tissue.pdf
Questions about this technology?